EP4483880A4 - Verwendung eines hpk1-inhibitors bei der behandlung von interferonbedingten erkrankungen - Google Patents

Verwendung eines hpk1-inhibitors bei der behandlung von interferonbedingten erkrankungen

Info

Publication number
EP4483880A4
EP4483880A4 EP23759416.3A EP23759416A EP4483880A4 EP 4483880 A4 EP4483880 A4 EP 4483880A4 EP 23759416 A EP23759416 A EP 23759416A EP 4483880 A4 EP4483880 A4 EP 4483880A4
Authority
EP
European Patent Office
Prior art keywords
hpk1
hibitor
interferon
treatment
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23759416.3A
Other languages
English (en)
French (fr)
Other versions
EP4483880A1 (de
Inventor
Wenjuan Wei
Tao Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asclepieion Pharmaceutical Co Ltd
Original Assignee
Asclepieion Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asclepieion Pharmaceutical Co Ltd filed Critical Asclepieion Pharmaceutical Co Ltd
Publication of EP4483880A1 publication Critical patent/EP4483880A1/de
Publication of EP4483880A4 publication Critical patent/EP4483880A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP23759416.3A 2022-02-23 2023-02-23 Verwendung eines hpk1-inhibitors bei der behandlung von interferonbedingten erkrankungen Pending EP4483880A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210168693.XA CN116672450A (zh) 2022-02-23 2022-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用
PCT/IB2023/051675 WO2023161844A1 (zh) 2022-02-23 2023-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用

Publications (2)

Publication Number Publication Date
EP4483880A1 EP4483880A1 (de) 2025-01-01
EP4483880A4 true EP4483880A4 (de) 2026-03-11

Family

ID=87764942

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23759416.3A Pending EP4483880A4 (de) 2022-02-23 2023-02-23 Verwendung eines hpk1-inhibitors bei der behandlung von interferonbedingten erkrankungen

Country Status (8)

Country Link
US (1) US20250161319A1 (de)
EP (1) EP4483880A4 (de)
JP (1) JP2025508495A (de)
KR (1) KR20240163080A (de)
CN (1) CN116672450A (de)
AU (1) AU2023226510A1 (de)
CA (1) CA3244921A1 (de)
WO (1) WO2023161844A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023143135A1 (zh) * 2022-01-28 2023-08-03 赛诺哈勃药业（成都）有限公司 一种喹唑啉衍生物及其用途
WO2025228828A1 (en) * 2024-04-29 2025-11-06 Merck Patent Gmbh Carboxamide compounds for the treatment and prevention of viral diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183964A1 (en) * 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
WO2020023560A1 (en) * 2018-07-24 2020-01-30 F. Hoffmann-La Roche Ag Isoquinoline compounds and uses thereof
WO2021004535A1 (en) * 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Cinnolines as inhibitors of hpk 1
KR20210143131A (ko) * 2020-05-19 2021-11-26 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US9682961B2 (en) * 2013-12-06 2017-06-20 Carna Biosciences, Inc. Quinazoline derivative
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
CN114315798B (zh) * 2020-09-29 2025-03-25 安思科(苏州)医药科技有限公司 喹唑啉类化合物及其药物组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183964A1 (en) * 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
WO2020023560A1 (en) * 2018-07-24 2020-01-30 F. Hoffmann-La Roche Ag Isoquinoline compounds and uses thereof
WO2021004535A1 (en) * 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Cinnolines as inhibitors of hpk 1
KR20210143131A (ko) * 2020-05-19 2021-11-26 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HE TIAN-SHENG ET AL: "The Kinase MAP4K1 Inhibits Cytosolic RNA-Induced Antiviral Signaling by Promoting Proteasomal Degradation of TBK1/IKK[epsilon]", MICROBIOLOGY SPECTRUM, vol. 9, no. 3, 1 December 2021 (2021-12-01), US, pages e0145821, XP093360088, ISSN: 2165-0497, DOI: 10.1128/Spectrum.01458-21 *
HERNANDEZ SAIRY ET AL: "The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function", CELL REPORTS, vol. 25, no. 1, 1 October 2018 (2018-10-01), US, pages 80 - 94, XP055881180, ISSN: 2211-1247, Retrieved from the Internet <URL:https://www.cell.com/cell-reports/pdf/S2211-1247(18)31442-6.pdf> DOI: 10.1016/j.celrep.2018.09.012 *
See also references of WO2023161844A1 *

Also Published As

Publication number Publication date
CA3244921A1 (en) 2025-06-13
CN116672450A (zh) 2023-09-01
AU2023226510A1 (en) 2024-10-10
KR20240163080A (ko) 2024-11-18
WO2023161844A1 (zh) 2023-08-31
EP4483880A1 (de) 2025-01-01
JP2025508495A (ja) 2025-03-26
US20250161319A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
EP4483880A4 (de) Verwendung eines hpk1-inhibitors bei der behandlung von interferonbedingten erkrankungen
EP3900717C0 (de) Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen
EP3976010A4 (de) Oligonukleotide und verfahren zur verwendung zur behandlung von neurologischen krankheiten
EP4014975C0 (de) Verwendung von bromophenol-pyrazolin-verbindungen in der behandlung von erkrankungen mit dem porzinen coronavirus
EP4164651C0 (de) 5-amino-2,3-dihydro-1,4-phthalazinedion zur verwendung bei der behandlung von coronavirusinfektionen
EP4122474A4 (de) Verwendung von mitochondrien zur behandlung und/oder prävention von sehnenschäden oder verwandten erkrankungen
EP4216962A4 (de) Line-1-inhibitoren zur behandlung von krankheiten
EP4031124A4 (de) Verwendung von ppar-delta-agonisten bei der behandlung von nierenkrankheiten
EP4404932A4 (de) Prc2-inhibitoren zur verwendung bei der behandlung von bluterkrankungen
EP4469085A4 (de) Anti-musk-antikörper zur verwendung bei der behandlung neuromuskulärer erkrankungen
EP4446407A4 (de) Manipulierter mikroorganismus zur behandlung von hyperphenylalaninämie und verwendung davon
EP4352265A4 (de) Verwendung der krebszellexpression von cadherin 12 und cadherin 18 zur behandlung von blasenkrebs
EP4205734C0 (de) Alpha-asaron zur verwendung bei der behandlung von hämorrhagischem schlaganfall
EP4236951A4 (de) Pde9-inhibitoren zur behandlung von herzinsuffizienz
EP4362965A4 (de) Verwendung eines lrp1-inhibitors bei der behandlung von notch-signalabhängigen erkrankungen
EP4132571C0 (de) Salmonidölzusammensetzungen zur verwendung bei der behandlung von mit eosinophilen in zusammenhang stehenden entzündlichen und respiratorischen zuständen
JOP20240149A1 (ar) مثبطات bcl-2 (الخلية ب لمفومة 2)
EP4422416A4 (de) Buvinkonas sp zur verwendung bei der vorbeugung und behandlung von krankheiten
EP4351590C0 (de) Glucose-methotrexat-konjugat zur verwendung bei der vorbeugung oder behandlung von autoimmunerkrankungen
EP4277620C0 (de) Tetrahydro-spiroindolin-pyrrolopyrrol-trione-inhibitoren der nrf2-beta-trcp-wechselwirkung zur verwendung bei der behandlung von fettlebererkrankung
EP4415707A4 (de) Verwendung von inhibitoren von proteinen der yth-domäne bei der behandlung von kognitiven oder entwicklungsstörungen
EP4452251A4 (de) Zusammensetzungen und verfahren zur verwendung zur behandlung von 12-lipoxygenase(12-lox)-vermittelten erkrankungen
EP4453027A4 (de) Anti-sars-cov-2-spike (s)-antikörper und deren verwendung bei der behandlung von covid-19
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
EP4125886C0 (de) Verwendung von thienopyridonderivaten zur behandlung von adrenoleukodystrophie oder adrenomyeloneuropathie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUANG, TAO

Inventor name: WEI, WENJUAN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260209

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/517 20060101AFI20260203BHEP

Ipc: A61K 31/5377 20060101ALI20260203BHEP

Ipc: A61K 31/4725 20060101ALI20260203BHEP

Ipc: A61K 31/496 20060101ALI20260203BHEP

Ipc: A61P 31/12 20060101ALI20260203BHEP